AbbVie has acquired global rights to a trispecific antibody, ISB-2001, from IGI Therapeutics for $700 million upfront, with potential milestone and royalty payments reaching nearly $2 billion. The investigational drug targets CD3, BCMA, and CD38 to treat relapsed or refractory multiple myeloma and is in early phase 1 trials, benefiting from orphan drug and fast track designations. AbbVie intends to explore additional autoimmune indications and leverages the antibody’s multifunctional mechanism to potentially overcome resistance seen in current treatments.